Evidence map›Paper›PMID 25958249›Full record

ArticleNeurobiology of disease2015

Botulinum toxin in migraine: Role of transport in trigemino-somatic and trigemino-vascular afferents.

Roshni Ramachandran, Carmen Lam, Tony L Yaksh

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurobiology of disease, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 40 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Headache Medicine Grand Challenge: Headache: A New Frontier, A New Challenge.Frontiers in pain research (Lausanne, Switzerland) · 2021
    Article
  10. Double-Binding Botulinum Molecule with Reduced Muscle Paralysis: Evaluation in In Vitro and In Vivo Models of Migraine.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2021
    Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Neurogenic inflammation and its role in migraine.Seminars in immunopathology · 2018
    Review
  16. Article
  17. Article
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Roshni RamachandranAnesthesiology Research, Department of Anesthesiology, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA.
Carmen LamAnesthesiology Research, Department of Anesthesiology, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA.
Tony L YakshAnesthesiology Research, Department of Anesthesiology, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA. Electronic address: tyaksh@ucsd.edu.
University of California, San Diego · US

Funding

The Pharmacology of Spinal AnalgesicsR01DA002110 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI YAKSH, TONY L. · 1985 to 2014
$3.8M
NIDA NIH HHS DA02110NIDA NIH HHS R01 DA002110
6 · The paper itself

Abstract

Migraine secondary to meningeal input is referred to extracranial regions innervated by somatic afferents that project to homologous regions in the trigeminal nucleus caudalis (TNC). Reported efficacy of extracranial botulinum toxin (BoNT) in treating migraine is surprising since a local extracranial effect of BoNT cannot account for its effect upon meningeal input. We hypothesize that intradermal BoNT acts through central transport in somatic afferents. Anesthetized C57Bl/6 mice (male) received unilateral supraorbital (SO) injections of BoNT-B (1.5 U/40 μl) or saline. 3 days later, mice received ipsilateral (ipsi)-SO capsaicin (20 μl of 0.5mM solution) or meningeal capsaicin (4 μl of 0.35 μM). Pre-treatment with ipsi-SO BoNT-B i) decreased nocicsponsive ipsilateral wiping behavior following ipsi-SO capsaicin; ii) produced cleavage of VAMP in the V1 region of ipsi-TG and in TG neurons showing WGA after SO injection; iii) reduced expression of c-fos in ipsi-TNC following ipsi-SO capsaicin; iv) reduced c-fos activation and NK-1 internalization in ipsi-TNC secondary to ipsi-meningeal capsaicin; and vi) SO WGA did not label dural afferents. We conclude that BoNT-B is taken up by peripheral afferents and transported to central terminals where it inhibits transmitter release resulting in decreased activation of second order neurons. Further, this study supports the hypothesis that SO BoNT exerts a trans-synaptic action on either the second order neuron (which receives convergent input from the meningeal afferent) or the terminal/TG of the converging meningeal afferent.

Indexed as

Afferent PathwaysAnimalsBotulinum Toxins, Type ACapsaicinDisease Models, AnimalDNA-Binding ProteinsFaceMaleMembrane Transport ModulatorsMeningesMice, Inbred C57BLMigraine DisordersNerve Tissue ProteinsNeurons, AfferentNociceptive PainNuclear ProteinsBotulinum Toxins, Type ACapsaicinDNA-Binding ProteinsMembrane Transport ModulatorsNerve Tissue ProteinsNeuN protein, mouseNuclear ProteinsProto-Oncogene Proteins c-fosReceptors, Neurokinin-1rimabotulinumtoxinBSNARE ProteinsBotulinum toxinMigraineReferred painTranscytosisTrans-synaptic

Identifiers

PMID25958249
PMCPMC4458441
OpenAlexW318869472

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.